SafeRx Pharmaceuticals is developing Alcohol-Resistant Opioids (ARO) using a proprietary platform to mitigate the risks associated with the concurrent use of opioids and alcohol, which can lead to respiratory failure and overdose. This technology aims to provide a safer alternative for patients at risk of opioid overdose, potentially saving tens of thousands of lives annually.
Funding
$5.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The concurrent use of opioids and alcohol can lead to respiratory failure and overdose, a significant contributor to opioid-related fatalities. Physicians currently lack effective pharmaceutical options to prevent patients from experiencing the dangers of this combination.
Solution
SafeRx Pharmaceuticals is developing Alcohol-Resistant Opioids (ARO) using a proprietary platform designed to mitigate the risks associated with the combined consumption of opioids and alcohol. The ARO technology aims to prevent the dangerous interaction between opioids and alcohol, which can severely impair breathing. This approach offers a safer alternative for patients at risk, with the potential to significantly reduce opioid overdose deaths related to alcohol consumption. The company believes its ARO technology has the potential to become a new standard of care for at-risk patients.
Target Audience
The primary target audience includes prescribing physicians seeking safer opioid options for patients at risk of alcohol co-ingestion, as well as patients who require opioid pain management but may be susceptible to concurrent alcohol use.
Features
- Proprietary ARO platform designed to prevent the interaction of opioids and alcohol.
- Formulation intended to maintain opioid efficacy while negating the respiratory depressant effects of alcohol.
- Potential to reduce the incidence of opioid-related overdose deaths involving alcohol.